OncoImmunology · 2018 · 60 citations · 53 references
MedicineOncologyPharmacologyImmunopharmacologyImmunotherapyMolecular OncologyCancer ImmunotherapyHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyImmunomodulatory DrugsMultiple MyelomaDaratumumab TherapyImmunomodulatory EffectsMultiple Myeloma TherapyMultiple Myeloma TreatmentMyeloma PathogenesisProteasome Inhibitor TherapyProteasome InhibitorsRelapsed Multiple Myeloma
, independent of its function as an immune activator. In conclusion, our data show that Dara impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
53
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +16
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text